期刊文献+

炎症因子、免疫细胞和纤维蛋白原联合检测在COPD中的应用

Application of combined detection inflammatory factor, immune cells and fibrinogen in COPD
下载PDF
导出
摘要 目的:探讨血清炎症因子、免疫细胞联合纤维蛋白原在COPD患者中水平变化,并探讨其与感染细菌类型的关系。方法:回顾性分析我科收治的50例COPD患者作为观察组,测定血清炎症因子IL-6、IL-8和纤维蛋白原水平,同时测定中心粒细胞和淋巴细胞水平,并计算比值(NLR);选取同期在我院体检的健康人50例作为对照组,观察血清学指标与肺功能指标的关系,并对患者进行三年随访,观察其与预后的关系。结果:COPD患者血清IL-6、IL-8、NLR和纤维蛋白原水平明显高于正常人,其差异有统计学意义(P〈0.05);IL-6、IL-8、NLR和纤维蛋白原水平越高,肺功能指标越差,其相关性系数为0.87,差异有统计学意义(P〈0.05);随访三年后,血清IL-6、IL-8、NLR和纤维蛋白原水平越高,死亡率越高。结论:血清炎症因子IL-6、IL-8、NLR和纤维蛋白原联合检测可以明确诊断COPD,同时间接判断肺功能和预后,具有重要的临床意义。 Objective:To investigate the value of serum FBG combined with inflammatory cytokines and immune cells in the patients with COPD , and to explore its relationship with theinfection of bacteria types.Methods:A retrospective analysis of 50 cases of COPD treated in our hospital were as the observation group, the serum inflammatory cytokines IL-6, IL-8 and fibrinogen, and select the same period in healthy elderly physical examination in our hospitalas control group, to observe the relationship between the serum and lung function index, andwere followed for three years to observe patients. Its relationship with the prognosis.Results: The serum COPD in patients with IL-6, IL-8 and fibrinogen levels were significantly higher than that of normal people, the difference was statistically significant (P〈0.05). IL-6, IL-8 andfibrinogen level is higher, the worse lung function indexes, the correlation coefficient was 0.87,the difference was statistically significant (P〈0.05); after three years of follow-up, the levels of serum IL-6, IL-8 and fibrinogen level is higher, the higher death rate.Conclusions:The serum levels of inflammatory cytokines IL-6, IL-8 and fibrinogen detection can diagnose COPD, andindirect judgment of pulmonary function and prognosis has important clinical significance.
作者 王淑杰
出处 《医学检验与临床》 2015年第5期6-8,共3页 Medical Laboratory Science and Clinics
关键词 慢性阻塞性肺疾病 炎症因子 纤维蛋白原 Chronic obstructive pulmonary disease Inflammatory factor Fibrinogen
  • 相关文献

参考文献15

  • 1Malin A.Review SeriesOld age:Pneumonia in old age[J].Chronic Respiratory Disease,2011,8(3):207-210.
  • 2Rubinsztajn R,PrzybyOOowski T,Maskey-Warzechowska M,et al..GOLD 2011-COPD from a new perspective[J].Polski Merkuriusz Lekarski Organ Polskiego Towarzystwa Lekarskiego,2013,202(34):192-195.
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8234
  • 4Pridgeon C,B ugeon L,D onnelly L,et a.Reg u lation of IL-17 in chronic inflam mation in the human Iung[J].Clin Sci(Lond),2011,120(12):515-524.
  • 5慢性阻塞性肺疾病病情严重程度评估系统在中国应用的专家共识[J].中华结核和呼吸杂志,2013,36(6):476-478. 被引量:55
  • 6Li N,H-kem aJR,L ew a n dow ski RP,eta.A m bient ultrafine patticles provide a strong adjuvan t effect in the secondary im mune response:im plication for traffic related asthm a f Iares[J].A m J Physiol Lung Cell Mol Physiol,2010,299(3):374-383.
  • 7Zhang L,C heng Z,Liu W,et a.E xpr e ssion oflnterleukin(IL )-10IL-17 A and IL-22 in Serum and Sputum of Stable Chronic Obstructive Pulmonary D isease Patients[J].COPD,2013,10(4):459-465.
  • 8LiG.ProfD enisE.O D onnelhpersonalized treatment ofC OPD[J].J T horac D is,2014,6(2):177-180.
  • 9王红阳,郭秀华,戈艳蕾,王立民,付爱双.小剂量肝素对老年AECOPD患者疗效及Fbg、Hs-CRP、TNF-α的影响[J].实用医学杂志,2013,29(20):3312-3314. 被引量:22
  • 10Takahashi T.Annual FEV I changes and numbers of circulating endothelial microparticles in patients with COPD:a prospective study[J].BMJ Open,2014,4(3):4571-4572.

二级参考文献32

  • 1黄尉国,王鸿利,张颖琪,朱立红,李耀辉,王学锋,程寅琳,邵慧珍,张鲁,葛维成.血浆D-二聚体检测及其临床应用[J].中华医学检验杂志,1995,18(2):71-74. 被引量:318
  • 2有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 3周永列,刘建栋.D-二聚体的测定及其临床意义[J].国外医学(临床生物化学与检验学分册),1996,17(1):4-6. 被引量:121
  • 4Danl,Tybjaerg - Hansen A, Vestbo J, et al. Elevated plasma fibringgen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Grit Care Med,2001, 164(6) :1008.
  • 5阮英茆,中华结核和呼吸杂志,1991年,14卷,5页
  • 6团体著者,中华病理学杂志,1990年,19卷,22页
  • 7程显声,中华结核和呼吸杂志,1984年,7卷,78页
  • 8朱元珏 陈文彬.呼吸病学[M].北京:人民卫生出版社,2002.609-616.
  • 9GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
  • 10Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.

共引文献8771

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部